Image via WikipediaPR NewsWire's Coverage of Spherix
Positive Clinical Trial Results were concluded for Type 2 Diabetes. This stock is a buy right now. It is very low priced. Trading was halted today. Expect modest returns tomorrow October 8th. This is a competitive market for Diabetes Drugs. Hopefully, getting FDA Approval soon could allow a gain in Market Share.
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
